NasdaqGS:BCYCBiotechs
Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus Narrative
Bicycle Therapeutics (BCYC) has just posted its FY 2025 third quarter numbers, with revenue of about US$11.7 million and a basic EPS loss of US$0.85. Trailing twelve month figures show revenue of roughly US$28.3 million and a basic EPS loss of US$3.62. Over recent quarters, revenue has ranged from US$2.9 million to US$11.7 million, while quarterly basic EPS losses have moved between US$0.74 and US$1.14. This gives investors a clearer sense of a business that appears to be in investment mode...